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Abstract
The role of biomarkers in drug discovery and development has gained precedence over the years. As
biomarkers become integrated into drug development and clinical trials, quality assurance and in
particular assay validation becomes essential with the need to establish standardized guidelines for
analytical methods used in biomarker measurements. New biomarkers can revolutionize both the
development and use of therapeutics, but is contingent upon the establishment of a concrete validation
process that addresses technology integration and method validation as well as regulatory pathways
for efficient biomarker development. This perspective focuses on the general principles of the
biomarker validation process with an emphasis on assay validation and the collaborative efforts
undertaken by various sectors to promote the standardization of this procedure for efficient biomarker
development.
Introduction
Biomarkers are playing an increasingly important role in drug discovery and development from
target identification and validation to clinical application, thereby making the overall process
a more rational approach. The potential use of biomarkers in each phase of the drug
development process is summarized in Table 1 (1). The incorporation of biomarkers in drug
development has clinical benefits that lie in the screening, diagnosing, or monitoring of the
activity of diseases or in assessing therapeutic response. The development and validation of
these mechanism-based biomarkers serve as novel surrogate endpoints in early phase drug
trials. This has created a much appreciated environment for protein biomarker discovery efforts
and the development of a biomarker pipeline which resembles the various phases of drug
development. The components of the biomarker development process include discovery,
qualification, verification, research assay optimization, clinical validation and
commercialization (2).
The role of biomarkers in rational drug development has been a major focus of the Food and
Drug Administration (FDA) critical path initiative and the National Institutes of Health (NIH)
roadmap (3). While the overwhelming majority of biomarkers are proteins used as surrogate
end points for drug development, diagnostic biomarkers may also prove useful for
understanding the biology of the disease. Successful biomarker development depends on a
series of pathway approach that originates from the discovery phase and culminates in the
clinical validation of an appropriately targeted biomarker. Much emphasis has been placed on
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the paradigm of biomarker translation specifically on the principles of biomarker validation in
clinical trials and the articles in this edition of CCR Focus will address various issues along
the validation pathway including the analysis of microarray datasets (4), the validation of
predictive models (5), the design of clinical trials using genomics (6), and the overall statistical
challenges that exist (7). New biomarkers can revolutionize both the development and use of
therapeutics, but is contingent upon the establishment of a concrete validation process that
addresses technology integration and method validation as well as regulatory pathways for
efficient biomarker development. This perspective will feature highlights on the biomarker
validation process and includes a discussion on analytical method validation.
Biomarker Definitions
Numerous publications have described the application of biomarkers in drug development
utilizing various nomenclatures to describe distinct aspects of this process. We begin with the
standardization of terminology for ease of understanding the biomarker literature. A consensus
definition of a biomarker is a factor that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or pharmacological responses to a
therapeutic intervention (8). A clinical endpoint is defined as a variable that measures how
patients feel, function, or survive whereas a surrogate endpoint is a biomarker that is intended
to substitute for a clinical endpoint. In this case, a surrogate endpoint is expected to predict
clinical benefit. Examples of surrogate endpoints and clinical endpoints are provided in Table
2.
Another critical distinction should be made when a biomarker undergoes analytical method
validation versus clinical qualification. Analytical method validation is the process of assessing
the assay, its performance characteristics, and the optimal conditions that will generate the
reproducibility and accuracy of the assay. Clinical qualification is the evidentiary process of
linking a biomarker with biological processes and clinical endpoints (9). While “validation”
and “qualification” or “evaluation” have been used interchangeably in the literature, the
distinction should be made to properly describe the particular phase the biomarker is
transitioning through in the drug development process. As such, the term “validation” is
reserved for analytical methods, and “qualification” for biomarker clinical evaluation to
determine surrogate endpoint candidacy (8,9). Both validation and qualification processes are
intertwined and hence their integration guides biomarker development with the principle of
linking the biomarker with its intended use (see section on Fit-for-Purpose Method Validation)
(10).
Biomarker Qualification Process Map
The FDA has issued guidance for industry on pharmacogenomic data submissions and in
classifying the various types of genomic biomarkers and their degree of validity: exploratory
biomarkers, probable valid biomarkers and known valid biomarkers.1 Exploratory biomarkers
lay the groundwork for probable or known valid biomarkers and can be used to fill in gaps of
uncertainty about disease targets or variability in drug response, bridge the results of animal
model studies to clinical expectation, or used for the selection of new compounds (11).
Examples of exploratory biomarkers include the use of gene panels used for preclinical safety
evaluation or the evaluation of vascular endothelial growth factor as a target to assess the
efficacy of angiogenesis inhibitors. For an exploratory biomarker to achieve the status of
probable valid biomarker it needs to be “measured in an analytical test system with well-
established performance characteristics and for which there is an established scientific
1US Food and Drug Administration. Guidance for industry: Pharmacogenomic data submissions, 2005. Available from:
http://www.fda.gov/cder/guidance/6400fnl.pdf
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framework or body of evidence that elucidates the physiologic, toxicologic, pharmacologic,
or clinical significance of the test results.” A probable valid biomarker appears to have
predictive value for clinical outcomes but has not been independently replicated or widely
accepted. The advancement from probable valid to known valid lies in the achievement of a
broad consensus in cross-validation experiments which include the independent validation of
the biomarker by replicating the outcome at different sites. Thus, a known valid biomarker is
defined as “a biomarker that is measured in an analytical test system with well-established
performance characteristics and for which there is wide spread agreement in the medical or
scientific community about the physiologic, toxicologic, pharmacologic, or clinical
significance of the test results.” That is, the scientific community at-large accepts these known
valid biomarkers to predict clinical or preclinical outcomes. Examples of such valid genomic
biomarkers that are listed on the labels of FDA-approved drug products are presented in Table
3.
The qualification process is introduced to bridge the gap from an exploratory biomarker to a
known valid biomarker status keeping in mind that a validation process requires a consensus
on an efficient and transparent process map for genomic biomarker validation. A qualification
process map has been proposed by the FDA that evaluates exploratory genomic biomarkers of
preclinical drug safety to assess the potential of genomic technologies in mock submission
(12,13) and identify key parameters that can be used to determine the success of these
biomarkers in voluntary genomic data submission (14). The proposal transitions an exploratory
biomarker to a known valid genomic biomarker through a series of phases from discovery to
method development to validation studies and cross-validation consortium (11). In the case of
a process map that involves the validation of genomic biomarkers in clinical trials, the
regulatory agency will review the biomarker validation package in terms of the usefulness of
the biomarker in predicting clinical benefit (11). While this particular qualification process
addresses genomic biomarkers, its application can be further extended to other types of
biomarkers (e.g., protein or diagnostic biomarkers) granted the qualification approach remains
intact. Figure 1 shows the integration of the FDA biomarker qualification process along the
phases of the drug development process.
The inclusion of biomarkers in drug development and regulatory review will improve the
efficiency of the biomarker development process. Biomarker qualification is also observed in
the co-development of biomarkers (in the form of diagnostic tests) and drugs with the use of
these biomarkers limited to the drug's application (11).2 Co-development imposes the necessity
to generate specific guidelines describing analytical test validation (sensitivity and specificity
of the assays), clinical test validation (ability of the assays to detect and predict diseases), and
clinical utility.3 Furthermore, biomarkers play a significant role in adaptive trial designs in
which patient population stratification and efficacy determination is based on biomarker
readouts (15). Adaptive trials attempt to maximize the statistical power of the study with a
small sample size. The integration of biomarkers into drug development is further discussed
in the section below.
Fit-for-Purpose Method Validation
It is important to point out that biomarker method validation is distinct from pharmacokinetic
(PK) validation and routine laboratory validation. The FDA has issued guidance for industry
on bioanalytical method validation for assays that support PK studies that are specific for small-
2US Department of Health and Human Services, Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of
Approved Drug Labels, 2007. Available from: http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm
3US Department of Health and Human Services, Food and Drug Administration. Drug-Diagnostic Co-Development Concept Paper,
2005. Available from: http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf
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molecule drugs and which are not directly related to the validation of biomarker assays.4
Whereas routine laboratory validation refers to laboratories that perform testing on human
specimens for diagnosis, prevention, or treatment of any disease and falls under the jurisdiction
of the Clinical Laboratory Improvement Amendments of 1988, there is little regulatory
guidance on biomarker assay validation. In October 2003, the American Association of
Pharmaceutical Scientists (AAPS) and the US Clinical Ligand Society (CLAS) co-sponsored
a Biomarker Method Validation Workshop to address the validation challenges of biomarker
assays in support of drug development (16). At this meeting it was concluded that biomarker
methods should not be validated by the same guiding principles developed for drug analysis
used in bioanalytical method validation. Hence, a “fit-for-purpose” approach for biomarker
method development and validation is derived with the idea that assay validation should be
tailored to meet the intended purpose of the biomarker study.
Method validation should demonstrate the reliability of the assay for the intended application
with the rigor of the validation process increasing from the initial validation proposed for
exploratory purposes to the more advanced validation dependent on the evidentiary status of
the biomarker (10). The fit-for-purpose method validation is an umbrella terminology that is
used to describe distinct stages of the validation process including pre-validation, exploratory
and advanced method validation, and in-study method validation (Figure 1). Method validation
is thus a continuous and iterative process of assay refinement with validation criteria that is
driven by the application of the biomarkers with increasing rigor at each successive validation
step and focusing on method robustness, cross-validation, and documentation control.
Technology Integration in Biomarker Validation: Choice of Assays
Before addressing the elements of biomarker assay development and method validation, it is
important to recognize that the biomarker method validation process begins with choosing the
right assay, followed by developing this assay into a validated method. Indeed, the integration
of various technologies proves pivotal to not only biomarker identification and characterization
but also validation. In fact, the platform applied in biomarker discovery can also be further
developed and used as an analytical platform. Biomarker measurement can be assessed at
different biological levels with different technologies; thus, the appropriate choice of assay
depends on the application of the biomarker and the limitations of the respective technology.
Various types of assays can be used in the biomarker method validation process and range from
the relatively low technology end such as immunohistochemistry (IHC) to immunoassays to
the high technology end including platforms for genomics, proteomics, and multiplex ligand-
binding assays.
A genomics approach consists of various methods that measure gene expression analysis, such
as in microarrays, which has become the standard technology used for target identification and
validation. Reverse transcription-polymerase chain reaction is a very sensitive, reproducible
technology and often time used to validate microarray-generated data. Comparative genomic
hybridization can be used to detect chromosomal alterations associated with certain cancers.
Proteomics involves global protein profiling to provide information about protein abundance,
location, modification, and protein-protein interactions. While proteomics is a discovery
technology, immunoassays are routinely used for protein biomarker assessments due to its
straightforward clinical application and translation into a potential diagnostic assay. The
multiplexing of protein assays can increase the throughput for simultaneous analysis of several
proteins; however, it is limited by the need to standardize assay conditions, the lost of sensitivity
4US Food and Drug Administration. Guidance for industry: Bioanalytical method validation, 2001. Available from:
http://www.fda.gov/cder/guidance/4252fnl.pdf
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over single assays, and the quality control of each analyte in the complete multiplex panel
(17).
Metabonomics (or metabolomics) is the profiling of endogenous metabolites in biofluids or
tissue for characterization of the metabolic phenotype. The analytical platforms used are based
on nuclear magnetic resonance spectroscopy and the combination of liquid chromatography
with mass spectroscopy. It is principally used in biomarker discovery although by definition
it is the ultimate end-point measurement of biological events. Yet the technology is limited by
the lack of comprehensive metabolite databases and throughput both of which affects data
analysis and interpretation. The integration of these technologies lends to the field of
bioinformatics where linking expression data derived from genomic/proteomic approaches to
target biological pathways can provide a comprehensive understanding of the disease biology
and further validating the application of the biomarker (18).
Furthermore, advances in novel imaging approaches also have profound implications for
biomarker development. Molecular and functional imaging technologies are used to assess cell
proliferation and apoptosis (e.g., 18F-fluoro-L-thymidine and 99mTcannexin imaging), cellular
metabolism (e.g., 18F-fluorodeoxyglucose positron emission tomography), and angiogenesis
and vascular dynamics (e.g., dynamic contrast-enhanced computed tomography and magnetic
resonance imaging). Therefore, making the right choice of assay is an important first step to
successful biomarker method validation. Validating the developed method or assay to reliably
measure the biomarker depends on a series of parameters that is addressed below.
Biomarker Analytical Method Validation
The key parameter assay elements of biomarker method validation are more complicated than
for the typical bioanalytical assay that follows good laboratory practice (GLP) guidelines.
Table 4 compares these two validation paradigms and highlights some of the validation
challenges encountered with biomarker assays. Biomarker assay development and method
validation is a complex process that depends on a number of parameters from the choice of the
matrix to maintaining sample integrity to assay standardization and accuracy.
Specifications for biological matrices need to be determined taking into consideration the site
of biomarker production and the physiology and distribution of the biomarkers. The first
challenge is to identify and select a meaningful sample matrix that can be readily accessible,
such as whole blood, plasma, serum, or urine. Sources of analytes can influence the validation
process as evidenced by feasibility in the acquisition of biological material during the study
such as in the collection of non-invasive (sputum, urine, feces, and saliva) versus minimally
invasive (blood or plasma) samples. If the method has sufficient sensitivity, then the preferred
matrix choice is based on ease of sample collection and analysis. However, if sensitivity is a
factor and measurement of the biomarker in the specified matrix poses as a challenge, then the
preferred matrix is chosen based on sample concentration even if this presents as a greater
challenge for sample collection and preparation.
In addition to the influence of sample sources, material collection and processing should be
examined in order to maintain sample integrity. It is important for researchers to realize that
biospecimen collection varies across populations; how they are handled and differences in
sample processing parameters can dramatically impact a trial's results. Thus, appropriate
conditions for collecting, handling, and storing study samples need to be standardized along
with adequate training of the clinical trial management personnel to preserve the analyte's
stability and integrity. Sample integrity can be affected by repeated cycles of freeze-thawing
specimens or by long-term storage and hence the stability of the sample becomes compromised.
Depending on the type of samples (biological fluids or tissues), minimization in variability at
each step of this procedure from collection to processing is critical to ensure consistent and
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valid analyte measurement at subsequent biomarker assays. For biological fluids, differences
in the handling of urine versus whole blood samples can affect the analytical assay and thus
optimization of a processing protocol is necessary and should be based on the specific
biomarker in addition to the source of analyte. Thus, standardization of sample collection
procedures and appreciation of the associated limitations allow this variability to be minimized.
Moreover, the integrity of reagents is another parameter that can also affect biomarker analysis.
Reagents such as antibodies are subject to their own problems of supply, stability, and quality
control as they themselves are derived from biologic sources.
Quality control (QC) measures should be undertaken to document analytical performance
during clinical studies and to determine the acceptance or rejection of an analytical run during
sample analysis (19). Similar to bioanalytical method validation, biomarker analysis requires
a systematic review of the analyte stability in calibration standards, QCs and study samples
(20). In general, QCs are prepared to evaluate the lower, middle, and upper limits of standard
curve ranges. While QC samples are used during study sample analysis to judge the
acceptability of assay runs, validation samples (VS) are used in assay validation experiments
to estimate intra- and inter-run accuracy/precision and stability. Wherease only three VS
concentrations are required in GLP bioanalytical assays (21,22), at least five different
concentrations of VS should be analyzed in duplicate on at least six different runs during the
pre-study validation because quantitative biomarker assays often exhibit nonlinear calibration
curves thus more VS are required (10,23).
Since biomarkers are endogenous substances, difficulty may arise in obtaining biomarker/
analyte-free matrices either to perform specificity studies on or to prepare for the calibration
curve. Most of the time, the target biomarker molecule is not available to act as a certified
calibration standard (19). Researchers then may rely on the use of a noncertified standard, a
recombinant protein, or a surrogate matrix in order to construct the calibration curve (10). If
assay standards are prepared in a non-authentic matrix, QC samples should be prepared and
tested in the same matrix as the study samples to demonstrate that the assay performance is
similar between authentic and non-authentic matrices (24). Parallelism studies should be
conducted when surrogate standards and matrices are used for calibration purposes. Dilution
linearity can also be problematic, as antibody and ligand-binding affinities can vary
significantly in different media. Other important components of biomarker assay validation
include the reference materials, precision and accuracy, dynamic range, sample recovery,
sample volumes, and instrument validation. Additionally, the variability in method validation
can also be affected by assay results at different locations and the correct calibration of the
assay at different test sites.
The technical validation of biomarkers depends on all aspects of the analytical method
including assay sensitivity, specificity, reliability and reproducibility (19,25-27). Specificity
refers to the assay's ability to clearly distinguish the analyte of interest from structurally similar
substances. Selectivity measures the degree to which unrelated matrix components cause
analytical interference. Precision is determined by the assay's repeatability and reproducibility,
which are factors used to quantitatively express the closeness of agreement among results of
measurements performed under specific conditions (28). Repeatability describes the
measurements that are performed under the same conditions, while reproducibility addresses
measurements performed under different conditions. The reproducibility of the assay relies on
its variability, levels of technical/instrumental and biological noise as well as different
validation phases of the method (pre-study and in-study validation of the method).
The acceptance criteria of the assay performance are established based on the study objectives
and the known assay variability (29). The nature of the assay methodology and the data
generated using that particular assay can influence the establishment of assay acceptance
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criteria. The categories of biomarker data that reflect the type of assay employed have been
defined at the AAPS/CLAS workshop (16). To aid in the formulation of a method validation
plan, a biomarker assay can be placed into various functional categories, each requiring a
distinct level of validation. A definitive quantitative assay makes uses of calibrators and a
regression model to calculate absolute quantitative values for unknown samples. The reference
standard must be well defined and fully representative of the biomarker. This type of assay can
be validated to be accurate and precise. A relative quantitative assay uses a response-
concentration calibration with reference standards that are not fully representative of the
biomarker. Because the calibration curve may utilize either a noncertified standard or surrogate
matrix or both, studies on parallelism and dilution linearity are necessary. Precision can be
validated but accuracy can only be estimated. A quasi-quantitative assay (possesses certain
attributes) does not use a calibration standard, but has a continuous response that is expressed
in terms of a characteristic of the test sample. Precision can be validated, but not accuracy
(16).
A qualitative assay generates categorical data that lack proportionality to the amount of analyte
in a sample. The data may be ordinal in that the assay relies on discrete scoring scales like
those often used for IHC or nominal such as the presence or absence of a gene product (10,
16). Qualitative assays are only required to show that they are sufficiently sensitive and specific
to detect the target analyte. In addition to assay functionality, ensuring that the degree of
validation performed reflects the level of importance of the biomarker itself is equally
important. Table 5 summarizes the validation parameters for each category of biomarker assay
as recommended by the AAPS/CLAS workshop.
What should be the acceptance criteria of the assay performance? Rather then setting the
acceptance criteria for precision and accuracy at a fixed value, as in GLP assays, biomarker
assays should but evaluated on a case per case basis, with ± 25% acting as default value (±
30% at the lower limit of quantitation, LLOQ) (30). In determining acceptance limits for QCs
during sample analysis, either a 4-6-X rule or establishing confidence intervals should be
considered (10,30). Such is the case for bioanalytical assays of small molecules where the
analytical run is accepted as valid when at least 67% (4/6) of the QCs fall within 15% of their
nominal values (the 4:6:15 rule; (21,22,31)). Since the target molecule is often present in pre-
dose samples or in the QC matrix, limitations are often placed on LLOQ.
In summary, there numerous factors that impact the biomarker method validation process
including the sources of variability in measurements, the intended application of a biomarker,
patient selection, sample collection and processing, and analytical validation. As such proper
method validation should be carried out in early clinical studies so that these analytical results
can be used to assess whether the method affords the sensitivity, precision, and robustness of
the assay. During early exploratory phases of drug development, it is not necessary to perform
full validation of biomarkers as long as the methods provide reliable data, information, and
knowledge (24). As drug development progresses, validation should keep pace with the
required precision and reliability needed to achieve the study objectives (24,26). Pre-study
validation should be completed before clinical studies are begun and should set the foundation
for establishing method acceptance criteria. In-study sample analyses and validation must use
QCs to document analytical performance during clinical studies (19). As we advance towards
the later stages of drug development, the impact of the biomarker data on decisions around
critical safety, efficacy, pharmacodynamic, or surrogate information increases. Thus, an
increased rigor in advanced method validation is undertaken as described in the scaled, fit-for-
purpose approach (Figure 1).
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Standardization and Validation through Collaboration
Recognizing the importance and impact of biomarkers coupled together with the complexity
that exists in the drug development process, researchers realized that there is much needed
standardization for biomarker development and have therefore joined forces in an effort to
integrate biomarkers into drug development. The most recent of these alliances is a consortium
called the Cancer Biomarkers Collaborative (CBC) comprised of the American Association
for Cancer Research, the FDA, and the National Cancer Institute with an initiative focused on
facilitating the use of validated biomarkers in clinical trials (32). The goal of the CBC is to
develop guidelines in the areas of biospecimens, assay validation, bioinformatics, and
information sharing. The CBC will recommend standards and specifications on how to collect
biospecimens and integrate them into drug trials such that the desired endpoint of the biomarker
measurement is reached and these endpoints can then be compared among clinical trials. Effort
in terms of validation is aimed at identifying and defining how to validate a biomarker assay
and make it eligible for inclusion into clinical trials. Hence, the need for a well-defined process
with consensus standards and guidelines for biomarker development, validation, qualification,
and use is apparent and an important priority of the collaboration. The CBC intends to pave a
regulatory pathway for biomarkers, as they transition from the development phase through the
FDA approval process and then on to clinical utility.
In addition to the CBC, other alliances in existence include partnerships with government,
industry, patient advocacy groups, and other non-profit private sector organizations. The
Biomarkers Consortium is a public-private biomedical research partnership formed by the
Foundation for the National Institutes of Health, the NIH, FDA, and the Pharmaceutical
Research and Manufacturers of America. The Biomarkers Consortium aims to rapidly identify
and qualify biomarkers, verify their individual value, and formalize their use in research and
regulatory approval to guide clinical practice. Therefore, these collaborative efforts among
various sectors have arisen to address the lack of standardized guidelines in biomarker
validation, particularly for method validation, and in doing so hope to promote an efficient
biomarker development process.
Integrating Biomarkers into Drug Development
Up to this point we have discussed the importance of biomarker method standardization and
validation. However, another challenge that remains to be addressed is in understanding how
to effectively and efficiently integrate biomarkers into the drug development process.
Biomarkers can play a pivotal role in facilitating drug development (Table 1), particularly in
oncology drug development where tumor markers appear to correlate with prognosis and
potentially be a valuable measure of treatment outcome. The incorporation of biomarkers as
surrogate endpoints of clinical efficacy and safety assessment are being intensely evaluated
and pursued in rational drug development, especially in the case of biomarker and drug co-
developments such as HER2 (also called ErbB2 and Neu) and the development of trastuzumab.
HER2 is a proto-oncogene that became a potential biomarker when studies showed that its
overexpression in breast cancer is associated with poor prognosis (33). The role of HER2 as a
clinically relevant biomarker led directly to the development of trastuzumab, a specific targeted
therapy of a recombinant monoclonal antibody directed against the extracellular domain of
HER2. HER2 as a biomarker was used for the selection of the appropriate patient populations
(that express or overexpress the oncogenic protein) in clinical trials and to evaluate potential
efficacy after therapeutic intervention. Indeed several clinical studies have confirmed that
patients with high levels of HER2 receptor overexpression (via IHC staining) are likely to
receive clinical benefit from therapy and that HER2 gene amplification (by fluorescence in
situ hybridization) is most predictive (34). As such, trastuzumab was subsequently approved
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in 1998 by the FDA as second-/third-line monotherapy or first-line therapy in combination
with paclitaxel for the treatment of HER2-overexpressing metastatic breast cancer (35-38).
Thus, biomarker-based patient selection in the early stages of the clinical trial process proves
to be critical to the evaluation of a targeted agent as demonstrated by the successful
development of trastuzumab.
Another example of the successful use of biomarkers in cancer drug development is the
development of imatinib mesylate. This molecular targeted drug is highly efficacious in chronic
myeloid leukemia (CML) (39) and gastrointestinal stromal tumor (GIST) (40,41). The BCR-
ABL fusion protein translocation in CML provided a biomarker and a therapeutic target for
this rationally designed small molecule. In clinical trials of imatinib, assessment of biomarker-
based responses facilitated proof of its clinical benefit in CML. Clinical benefit was determined
from evaluation of the molecular target in trials using conventional cytogenetics, fluorescence
in situ hybridization assays of the BCR-ABL translocation, and RT-PCR detection of BCR-
ABL transcripts, which are now used to guide treatment decisions (42). Treatment response
and dose optimization can be based on measuring the level of BCR-ABL kinase inhibition
achieved in vivo as determined by calculating the reduction in protein levels of phospho-CRKL
in mononuclear blood cells taken from CML patients (43).
Imatinib also inhibited the receptor tyrosine kinase encoded by the oncogene c-KIT and
expression of this oncogenic biomarker provided a rationale for its use in patients with GIST.
In addition, the response to imatinib is closely correlated with the presence and type of c-KIT
mutation, creating another role for these mutations to serve as biomarkers in treatment selection
for individuals with GIST (44-46). GISTs with the most common c-KIT exon 11 mutations
are associated with increased imatinib sensitivity, whereas the less common c-KIT exon 9
mutation are less sensitive to imatinib (47,48). GISTs lacking mutations in c-KIT or the
alternative receptor tyrosine kinase PDGFRA show much lower rates of response to imatinib
(47,48). Thus, the example of imatinib illustrates how biomarkers derived from BCR-ABL can
both stimulate initial drug discovery efforts and serve as a useful endpoint assessment of
treatment effect in biomarker-based patient and dose selection for imatinib therapy.
With these examples of biomarkers providing key rationale and endpoints in the development
of molecular targeted agents, biomarker-based drug development can be regarded as a proven,
successful strategy for developing novel anticancer drugs. The scope of evaluation and
validation of the biomarker will depend on its intended use as a marker of toxicity, safety, or
efficacy. These biomarkers may serve as surrogate endpoints that predict clinical outcomes.
As biomarkers are incorporated in drug development, regulatory approaches will be developed
and will be more stringent than that needed to guide early drug development to ensure that the
development, validation, and implementation of biomarkers into clinical trials is a safe,
effective, and efficient process.
Conclusions
The need for a standardized pathway approach towards the biomarker validation process is
becoming increasingly important given the recent surge in the biomarker development pipeline.
As biomarker research progresses towards establishing the fundamentals of personalized
medicine, the future of drug and biomarker co-development resides in identifying the right
population that would benefit from that drug. The significant effort and resources that are
invested in the development of these biomarkers will expand their roles as surrogate endpoints
and diagnostic indicators for disease screening, monitoring disease progression and treatment
efficacy, and in assessing patient outcome or identifying potential side effects such as in
toxicity. The emphasis now would be placed on biomarker assay development and method
validation to eliminate the failure of biomarkers that occur in the clinic as a result of poor assay
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choice and the lack of robust validation. Future advancements in biomarker research will be
heavily focused on transitioning biomarkers from the development and validation phases to
their clinical applications incorporated into drug trials.
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Integration of the biomarker assay validation and the qualification process with drug
development (see text for a description of each process).
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Table 1




Potential uses of biomarkers during drug development
Target discovery &
validation
• Biomarkers used to identify and justify targets for therapy such cellular growth factor receptors, signaling molecules, etc.
(e.g. HER2 proto-oncogene frequently amplified in breast cancer and associated with poor prognosis → this correlation
provided the rationale for anti-HER2 therapeutic strategies leading to the development of trastuzumab).
Lead discovery and
optimization
• Biomarkers used to determine target effects with target-associated assays to identify leads and evaluate the effects of molecular
targeted drugs in preclinical development.
• Lead agents developed against given target further optimized based on biomarker endpoints in model systems or animal
studies.
Preclinical studies • Development of appropriate animal models of cancer that feature biomarker properties comparable with those seen in patient
populations to enhance their utility as predictive models.
• Biomarkers can play an essential role in the validation of new disease models (e.g. transgenic mouse models of breast cancer
that overexpress HER2).
• Biomarkers are used to assess toxicity and safety of the drug.
Clinical trials • Biomarker-based studies can provide early evaluations of whether the drug is hitting the target (success or failure).
• Mechanism-based biomarkers can help guide rational selection of effective drug combinations.
• Optimization of dose and schedule can be based on pharmacological effects on biomarker-based end points rather than on
maximum tolerated dose.
• Biomarkers can serve as tools for the selection of appropriate patient populations or used to stratify patients based on
differential clinical response or to identify responders in a subpopulation.
• Development and validation of mechanism-based biomarkers that reflect disease activity or the interactions between disease
targets and targeted therapy may lead to new surrogate endpoints of clinical benefit.
• Selected biomarkers may have the potential to predict clinical outcome.
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Table 2
Examples of surrogate endpoints and clinical endpoints.
Disease Surrogate Endpoints Clinical Endpoints
Hypertension Blood pressure Stroke
Dyslipidemia Cholesterol, LDL Coronary artery disease
Diabetes Glycosylated hemoglobin (HbA1c) Retinopathy, nephropathy, neuropathy, heart disease
Glaucoma Intraocular pressure Loss of vision
Cancer Biomarkers Tumor shrinkage, Response rate Progression-Free Survival Overall Survival
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Table 3
Valid genomic biomarkers in the context of FDA-approved drug labels.
Genomic biomarker Context in label for which biomarker is valid Other drugs associated
with this biomarker
Representative label Test* Drug
c-KIT mutations+ Presence & type of GIST c-KIT
mutations (exon 11 vs. exon 9)
predicts sensitivity to imatinib
3 Imatinib mesylate
CCR5 - Chemokine C-C motif receptor Drug blocks CCR5 receptor on T-
cell that HIV binds to for entry
(use only in patients with CCR5-
tropic HIV-1 detectable)
1 Maraviroc
CYP2C9 variants CYP2C9 PM variants ↑ and EM
variants ↓ drug exposure and risk
3 Celecoxib
CYP2C9 mutations CYP2C9 mutations ↑ bleeding
risk thus requiring lower drug
dose
2 Warfarin
CYP2C19 variants CYP2C19 variants with genetic
defect leads to change in drug






CYP2D6 variants CYP2D6 PM variants ↑ and EM
variants ↓ drug exposure and
toxicity















Deletion of Chromosome 5q Cytogenetic abnormality in








EGFR mutations+++ EGFR mutations ↑ response in
NSCLC
3 Gefitinib Cetuximab
EGFR expression EGFR (+) expression required for
CRC
1** Cetuximab Panitumab, Gefitinib
Her2/neu overexpression or amplification Detection of Her2/neu
overexpression or amplification
required to select patients for
therapy in breast cancer
1 Trastuzumab Lapatinib
K-RAS mutations++++ K-RAS mutations confer
resistance to cetuximab in
colorectal cancer
3 Cetuximab
NAT (N-Acetyltransferase) variants NAT variants slow and fast
acetylators (slow acetylation ↑
drug exposure and toxicity)




Ph1 presence predict response-
Busulfan less effective in patients
with (Ph1-) chronic myelogenous
leukemia
3 Busulfan
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Genomic biomarker Context in label for which biomarker is valid Other drugs associated
with this biomarker
Representative label Test* Drug
Philadelphia (Ph1) chromosome-positive
responders
Ph1 presence predict response-
Dasatinib is indicated for adults
with (Ph1+) acute lymphoblastic
leukemia
1 Dasatinib
PML/RAR alpha gene expression Presence of PML/RAR (alpha)
fusion gene predicts response to
drug
3 Tretinoin Arsenic oxide
Protein C deficiencies Hereditary or acquired
deficiencies of protein C may ↑
risk of tissue necrosis
2 Warfarin
TPMT variants TMPT deficiency or mutation ↑
risk of myelotoxicity
2 Azathioprine
UCD deficiency Contraindicated in UCD patients;
evaluation for UCD prior to start
of therapy
2 Valproic acid Sodium phenylacetate and
sodium benzoate, sodium
phenyl buterate
UGT1A1 mutations UGT1A1 mutation ↑ drug
exposure and toxicity
2 Irinotecan
UGT1A1 mutations UGT1A1 mutation ↑ bilirubin
levels
3 Nilotinib
VKORC1 variants VKORC1 variants confer
sensitivity to warfarin thus ↓ dose
of warfarin
2 Warfarin
CRC: Colorectal cancer; CYP: Cytochrome P450; DPD: Dihydropyrimidine dehydrogenase; EGFR: Epidermal Growth Factor; EM: Extensive
Metabolizer; G6PD: Glucose-6-phosphate dehydrogenase; GIST: Gastrointestinal stromal tumor; HIV: Human immunodeficiency virus; NADH:
Nicotinamide adenine dinucleotide; NSCLC: Non-small cell lung cancer; PM: Poor Metabolizer; PML/RAR: Promyelocytic leukemia/Retinoic acid
receptor; TMPT: Thiopurine methyltransferase; UCD: Urea cycle disorders; UGT: UGD glucuronosyltransferase; VKORC1: Vitamin K epoxide reductase
complex.
This table is adapted from the following website: http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm.
CYP: Cytochrome P450; DPD: Dihydropyrimidine dehydrogenase; EGFR: Epidermal Growth Factor; EM: Extensive Metabolizer; G6PD: Glucose-6-
phosphate dehydrogenase; GIST: Gastrointestinal stromal tumor; HIV: Human immunodeficiency virus; NADH: Nicotinamide adenine dinucleotide;
NSCLC: Non-small cell lung cancer; PM: Poor Metabolizer; PML/RAR: Promyelocytic leukemia/Retinoic acid receptor; TMPT: Thiopurine
methyltransferase; UCD: Urea cycle disorders; UGT: UGD glucuronosyltransferase; VKORC1: Vitamin K epoxide reductase complex. This table is
adapted from the following website: http://www.fda.gov/cder/genomics/genomic_biomarkers table.htm.
*
Reference is made to the requirement of testing for the biomarker (1 = test required, 2 = test recommended, 3 = information only). The test recommendation
listed above is current and up-to-date at the time this article is written.
+
Recent studies have shown that c-KIT exon 11 mutations are most common for gastric GISTs and these mutants respond well to imatinib. The less
common c-KIT exon 9 mutations occur in intestinal GISTs and are less sensitive to imatinib (47,48). The current FDA-approved drug label for imatinib
does not contain this information.
++
Recent studies have shown that higher fluorouracil plasma levels correlated with acute grade 3 toxicity (49).
+++
Recent studies have shown that EGFR mutations and/or amplifications correlate with tyrosine kinase inhibitor activity (50,51). The current FDA-
approved drug label for gefitinib and cetuximab does not contain this information.
**
Although this is a required test, it is not a predictive marker of activity.
++++
Reference (52). The current FDA-approved drug label for cetuximab does not contain this information.
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Table 4
Comparison of bioanalytical assay and biomarker assay validation parameters.
Parameter Bioanalytical (GLP) assay Biomarker Assay
Assay method category Most are definitive quantitative Most are relative or quasi-quantitative
Regulatory requirement GLP No specific guidelines
Nature of analyte Exogenous Endogenous
Stability Drug standards, QCs, sample analyte stability often
good
Stability of standards & matrix analytes often
poor
Stability testing Freeze/thaw, bench top, long-term measured by
spiking biological matrix with drug
Freeze/thaw, bench top, storage stability with
study samples
Standards/Calibrators Standards prepared in study matrix; certified standard
readily available
Standards/calibrators made in matrix different
than study samples; certified standards not
available
Calibration model Mostly linear Choose appropriate calibration model fitting
method and tools
Quality controls Certified standard & blank patient sample matrix
available
Certified standard or blank matrix usually not
available; substitute with surrogate matrices
Validation sample & Quality control measurements Made in study matrix. 4-5 VS levels & 3 QC levels Made in study matrix. At least 5 VS levels & 3
QC levels. If study matrix is limited may use
surrogate matrix
Assay acceptance criteria 4-6-15 rule (for small molecules) 4-6-X rule or establish confidence interval
Precision/Accuracy Robust technology with acceptance criteria Variable; no acceptance criteria
Specificity/Selectivity Drugs not present in sample matrix; samples are
subject to clean-up & analyte recovery
Specificity issues: biomarkers present in sample
matrix; samples not subject to clean-up; assess
matrix effects & minimize; investigate sources of
interference
Sensitivity LLOQ defined by acceptance criteria Limited sensitivity & dynamic range; LLOQ &
LOD defined based on working criteria
GLP: Good laboratory practices; QC: Quality controls; VS: Validation sample; LLOQ: Lower limit of Quantitation; LOD: Limit of Detection
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Table 5
Summary of validation parameters applicable to each category of biomarker assay.
Definitive quantitative Relative quantitative Quasi-quantitative Qualitative
Validation Parameters
Sample stability X X X X
Reagent stability X X
Assay range X X X
Parallelism X X
Dilution linearity X X
Accuracy X X
Precision X X X
Sensitivity X X X X
Specificity X X X X
Example of assay Mass spectrometry ELISAs Immunogenicity immunoassays Immunohisto-chemistry
Clin Cancer Res. Author manuscript; available in PMC 2009 September 15.
